Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Oggero

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Journal of Hazardous Materials|November 22, 2005
A survey of accidents occurring during the transport of hazardous substances by road and railA Oggero, R M Darbra, M Muñoz, et al.
Neurology|March 4, 1998
Interferon treatment for multiple sclerosis: autoimmune complications may be lethalL Durelli, M R Bongioanni, B Ferrero, et al.
Neurology|October 24, 2001
Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MSL Durelli, B Ferrero, A Oggero, et al.
Journal of the Neurological Sciences|October 6, 2000
Does high-dose interferon beta-1b improve clinical response in more severely disabled multiple sclerosis patients?L Durelli, A Oggero, E Verdun, et al.
The Journal of Clinical Endocrinology and Metabolism|August 15, 2001
Thyroid function and autoimmunity during interferon beta-1b treatment: a multicenter prospective studyL Durelli, B Ferrero, A Oggero, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|March 26, 2002
Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?E Verdun, G Isoardo, A Oggero, et al.
Acta Neurologica Scandinavica|March 10, 2001
Anti-GM1 and anti-sulfatide antibodies in polyneuropathies. Threshold titers and accuracyG Isoardo, B Ferrero, P Barbero, et al.
Journal of the Neurological Sciences|November 1, 1996
Systemic high-dose recombinant-alpha-2a-interferon therapy modulates lymphokine production in multiple sclerosisM R Bongioanni, L Durelli, B Ferrero, et al.
Multiple Sclerosis and Related Disorders|July 23, 2023
Serum Neurofilaments are a reliable biomarker to early detect PML in Multiple Sclerosis patientsP Valentino, S Malucchi, C I Bava, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 18, 2001
Interferon-beta dose and efficacy: the OPTIMS studyL Durelli, A Oggero, E Verdun, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Journal of Hazardous Materials|November 22, 2005
A survey of accidents occurring during the transport of hazardous substances by road and railA Oggero, R M Darbra, M Muñoz, et al.
Neurology|March 4, 1998
Interferon treatment for multiple sclerosis: autoimmune complications may be lethalL Durelli, M R Bongioanni, B Ferrero, et al.
Neurology|October 24, 2001
Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MSL Durelli, B Ferrero, A Oggero, et al.
Journal of the Neurological Sciences|October 6, 2000
Does high-dose interferon beta-1b improve clinical response in more severely disabled multiple sclerosis patients?L Durelli, A Oggero, E Verdun, et al.
The Journal of Clinical Endocrinology and Metabolism|August 15, 2001
Thyroid function and autoimmunity during interferon beta-1b treatment: a multicenter prospective studyL Durelli, B Ferrero, A Oggero, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|March 26, 2002
Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?E Verdun, G Isoardo, A Oggero, et al.
Acta Neurologica Scandinavica|March 10, 2001
Anti-GM1 and anti-sulfatide antibodies in polyneuropathies. Threshold titers and accuracyG Isoardo, B Ferrero, P Barbero, et al.
Journal of the Neurological Sciences|November 1, 1996
Systemic high-dose recombinant-alpha-2a-interferon therapy modulates lymphokine production in multiple sclerosisM R Bongioanni, L Durelli, B Ferrero, et al.
Multiple Sclerosis and Related Disorders|July 23, 2023
Serum Neurofilaments are a reliable biomarker to early detect PML in Multiple Sclerosis patientsP Valentino, S Malucchi, C I Bava, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|October 18, 2001
Interferon-beta dose and efficacy: the OPTIMS studyL Durelli, A Oggero, E Verdun, et al.
Pageof 2